Collaborative Arrangements - Narrative (Details) $ in Thousands	1 Months Ended				3 Months Ended	12 Months Ended
	Jan. 31, 2024 USD ($)	Aug. 31, 2022 USD ($)	Dec. 31, 2015	Feb. 29, 2012	Jun. 30, 2023 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2025 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Oct. 31, 2020 USD ($)	Mar. 31, 2020 USD ($) plan	Dec. 31, 2019 USD ($)	May 31, 2019 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligations satisfied						$ 350	$ 10,121
Revenues						70,387	59,345	$ 70,143
Contract liabilities: deferred revenue						7,369	450
Product revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues						26,028	36,786	42,906
Research and development revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues						44,359	22,559	27,237
Supply Agreement | Product revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue								1,300
Technology Transfer Agreement | Research and development revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues						31,500
Enzyme Supply Agreement | Product revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues								3,200
Merck | Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Term of collaborative research and development agreement			5 years	5 years
Merck | Supply Agreement | Product revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligations satisfied						400	7,100	4,400
Merck Technology Transfer and License Agreements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue						6,300
Merck Technology Transfer and License Agreements | License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non refundable license payment									$ 2,500
Merck Technology Transfer and License Agreements | Technology Transfer Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non refundable and non creditable payment						37,800
Nestec Ltd. (Nestle Health Sciences) | Strategic Collaboration Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues						0	0	4,100
Nestlé Health Science | Acquisition Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues								5,000
Collaborative arrangement, upfront fee amount	$ 5,000
Novartis
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligations satisfied						600	1,000	1,100
Contract liabilities: deferred revenue																$ 5,000
Novartis | Computer equipment and software
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent annual receivable increase																$ 8,000
Revenue recognition, contingent annual payment period																4 years
Novartis | Milestone One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent receivable												$ 4,000
Novartis | Milestone Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent receivable											$ 5,000
Roche | Milestone One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue															$ 800
Roche | Milestone Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent receivable													$ 900
Roche | Research and development revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues							6,000
Takeda
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of program plans | plan														3
Revenue recognized, including opening balance						$ 0	800	2,000
Takeda | Up-front Payment
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue														$ 8,500
Pfizer | Research and development revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues					$ 5,000		$ 9,500	2,000
Pfizer | Enzyme Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligations satisfied								8,200
Contract with customer, liability, retainer fee		$ 25,900						$ 25,900
Contract with customer, liability, retainer fee, creditable percentage		90.00%
Contract with customer, liability, portion of retainer fee		$ 23,300								$ 23,300